Nasal Cannabinoid Delivery via Phospholipid Micelles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods of administering cannabidiol (CBD) have low bioavailability, with oral administration ranging from 6-15%, inhalation at 26-36%, and intranasal being the most effective at 34-46%, while conventional pharmaceutical methods face solubility issues with non-polar solvents, necessitating a safer, more effective, and convenient delivery method.
Innovation Solution
A nasal delivery composition using all-natural, mostly organic ingredients, including silver and plant extracts, to increase bioavailability, specifically designed as a nasal spray with a high concentration of medicinal cannabinoids, utilizing a silver solution and plant extracts like capsaicinoids and essential oils to enhance absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional pharmaceutical methods are used to formulate cannabinoids, then solubility issues arise with non-polar solvents, but using pharmaceutically acceptable solvents requires high concentrations which impose a ceiling on the dose
Solution Approach 1:
The patent uses phospholipids as intermediary substances that form micelles or liposomes to solubilize non-polar cannabinoids in aqueous environments. These phospholipid structures act as mediators between the hydrophobic cannabinoid molecules and the hydrophilic nasal mucosa, enabling high concentrations of cannabinoids to be delivered without requiring highly concentrated pharmaceutically acceptable solvents
Solution Approach 2:
The formulation creates composite structures where cannabinoids are encapsulated within phospholipid bilayers or micelles. This composite approach combines the solubility benefits of aqueous formulations with the high solubility capacity of non-polar environments within the phospholipid structures, effectively resolving the solubility-dose ceiling contradiction
2Ease of operation
If oral administration is used, then convenience is improved, but bioavailability is low at 6-15%
Solution Approach 1:
The patent extracts the absorption barrier problem from the oral administration route by switching to intranasal delivery. This removes the gastrointestinal tract and first-pass metabolism from the drug delivery pathway, thereby extracting the source of low bioavailability while maintaining convenience through a simple nasal spray application
3Quantity of substance
If inhalation is used, then bioavailability increases to 26-36%, but safety concerns arise from vaporization
Solution Approach 1:
The patent introduces phospholipid micelles and liposomes as intermediary delivery vehicles that replace the vaporization mechanism. These intermediaries carry cannabinoids directly to the nasal mucosa in a controlled, non-thermal manner, eliminating the harmful thermal effects of vaporization while maintaining efficient absorption through the nasal epithelium
4Quantity of substance
If intranasal administration is used, then bioavailability is maximized at 34-46%, but formulation complexity increases due to solubility requirements
Solution Approach 1:
The patent changes the physical-chemical parameters of the formulation by using phospholipid-based micelles and liposomes. This parameter change allows the formulation to maintain stability and solubility at lower concentrations compared to conventional approaches, reducing formulation complexity while achieving high intranasal bioavailability. The phospholipid structures naturally form stable colloidal systems that simplify the overall formulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly increases bioavailability and provides a safe, fast-acting, and discreet administration of cannabinoids, offering improved therapeutic effects with enhanced solubility and absorption through the nasal passage.
Implementation Method 1
facilitates effective delivery of a cannabinoid via the nasal passage
Implementation Method 2
increase the bioavailability of the cannabinoid
Data Source
AI summary
The present invention provides compositions for delivering cannabinoids to the nasal cavity. The subject invention utilizes a composition comprising one or more cannabinoids and an adjuvant mixture to enhance the delivery of the cannabinoid, benefitting the subject to whom the cannabinoid is delivered.